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Background: Physiologically, salivary secretion is controlled by cholinergic and adrenergic pathways but the role of ionic channels in this
process is not yet clearly understood. In cystic fibrosis (CF), most exocrine glands failed to response to β-adrenergic agonists.
Methods: To determine the implication of CFTR in this process, we measured in vivo the salivary secretion of Cftr+/+ and Cftr−/− mice in the
presence of 2 water-soluble benzo[c]quinolizinium derivatives; MPB-07 a potentiator of CFTR Cl− channel and MPB-05 an inactive
analogue. We also used genistein and its vehicle ethanol to confirm the implication of CFTR in salivary secretion.
Results: We showed that subcutaneous injection of MPB-07 in the mice cheek enhanced in a dose dependent manner the isoprenaline-
induced salivary secretion in Cftr+/+ but not in Cftr−/− mice. By contrast, MPB-05 did not activate the salivary secretion in Cftr+/+ mice. The
CFTR activator genistein (50 μM) significantly potentiated the secretory response of Cftr+/+ mice whereas its vehicle, ethanol, had no effect.
Conclusions: These results show for the first time in vivo pharmacological stimulation of salivary secretion by a water-soluble CFTR
potentiator, MPB-07 and by the isoflavone, ethanol-soluble genistein and suggest that this chloride channel plays an important role in
salivary gland physiology.
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The genetic disease cystic fibrosis (CF) is characterized
by defect of NaCl transport in exocrine tissues, among
them the sweat duct, the salivary glands and the exocrine
pancreas [1–3]. The sweat duct is the consensual model for
studying the effects of CF phenotype on absorptive tissue
function [1,2]. Salivary glands also represent a good model
to study fluid and electrolyte secretion. Saliva is secreted in
response to cholinergic and adrenergic agonists by the
coordinated action and regulation of multiple water and ion
transporters and ionic channels [4–7]. Fluid and electrolyte⁎ Corresponding author. Tel.: +33 549 45 37 29; fax: +33 549 45 40 14.
E-mail address: frederic.becq@univ-poitiers.fr (F. Becq ).
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doi:10.1016/j.jcf.2007.06.005transport is driven by transepithelial Cl− movement [4].
The opening of Cl− channels in the apical membrane of
salivary gland acinar cells initiates the fluid secretion
process, whereas the activation of Cl− channels in both the
apical and the basolateral membranes of ductal cells is
thought to be necessary for NaCl re-absorption [4,7].
Different classes of Cl− channels have been identified in
salivary cells; activated by intracellular Ca2+, gated by
cAMP, activated following changes in membrane potential
and cell volume [4–6]. An increase in the intracellular free
Ca2+ concentration is a dominant mechanism triggering
fluid secretion from acinar cells [5,6], while cAMP may be
required for efficient NaCl re-absorption in many ductal
cells [4,7]. The oral fluid originates from three pairs of
major salivary glands and several accessory glands.ed by Elsevier B.V. All rights reserved.
Fig. 1. Chemical structure of MPB-07 (10-chloro-6-hydroxybenzo[c]
quinolizinium chloride) and MPB-05 (6-hydroxybenzo[c]quinolizinium
chloride).
Fig. 2. Effect of MPB-07 compound on the salivary secretion of Cftr+/+ and Cftr−
iso+MPB-07 for Cftr+/+ (A) and Cftr−/− mice (B). Average of salivary rates of se
and Cftr−/− mice (D). For these experiments, 5≤n≤6.
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CF exocrine glands, because the secretory portion of CF
glands failed to respond to β-adrenergic agonists [2,8,9].
Based on these considerations, an in vivo mouse model
drug assay for CF has been developed using Cftr+/+ and
Cftr−/− mice to compare cholinergic and adrenergic
responses on saliva secretion [10]. It has been shown that
Cftr−/− mice salivary glands failed to respond to subcuta-
neous injection of the β-adrenergic agonist isoprenaline,
whereas the cholinergic response (atropine) remained
unchanged [8].
In the recent years, several pharmacological compounds
were shown to activate CFTR [11–16]. Among them we/− mice. Typical salivary response in the presence of isoprenaline alone or
cretion for Cftr+/+ and Cftr−/− mice (C). Total saliva secretion for Cftr+/+
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family as potentiators of CFTR chloride channels [11,12].
Here we show that the CFTR potentiators genistein and MPB-
07, but not the inactive analogue MPB-05, (see Fig. 1 for
chemical structures) stimulate in vivo the CFTR-dependent
salivary secretion.
2. Materials and methods
2.1. Animals
Females knockout Cftrtm1Unc mice [13,17] and their
female littermates control were obtained from CNRS-
CDTA (Centre de Distribution, Typage et Archivage animal,
Orléans, France). Mice were studied between the ages of 4
and 5 weeks. 24 control mice (Cftr+/+) and 10 knockout mice
(Cftr−/−) were used, with an average weight of 15.2±0.4 gFig. 3. Effect of genistein on the salivary secretion of Cftr+/+ mice. Salivary respon
genistein 50 μM (A). Average of salivary rates of secretion (B). Total saliva secretand 7.3±0.8 g, respectively (Pb0.0001). Mice were anes-
thetised with a ketamine/xylazine solution, a procedure
approved by the local ethical committee (stock solution of
ketamine 10 mg/ml and xylazine 1.5 mg/ml in NaCl 0.9%).
An intraperitoneal injection of 100 μl per 10 g of body weight
was performed. At the end of the experiment, mice, who were
always quiescent, returned to the animal house. The same
animal could be used for a new assay two days later.
2.2. Salivary secretion assay
The experimental procedure used for these experiments
was recently described [10]. Briefly, quiescent mice were
maintained in supine orientation with adhesive tape. Sub-
cutaneous injection of pharmacological agent was performed
in the cheek and saliva was collected with small pieces of
Whatman paper (2mm×25mm) inserted in themouth near tose in the presence of isoprenaline+ethanol 0 1% compared to isoprenaline+
ion (C). For these experiments, 3≤n≤4.
Fig. 4. Dose-dependent effect of MPB-07 on salivary secretion of Cftr+/+
mice. (A) curves showing the rate of salivary secretion stimulated by
increasing doses of MPB-07 in presence μM isoprenaline. (B) Mean total
saliva secreted during of 10stimulation by various doses of MPB-07 as
indicated. For these experiments, 5≤n≤6.
131S. Noël et al. / Journal of Cystic Fibrosis 7 (2008) 128–133the previously injected cheek. Every 3 or 4 min, a piece of
paper was removed and replaced with a second. At the end of
the experiment, the net weight of saliva secreted during the
collection period was evaluated. For all experiments, basal
salivary secretion was inhibited by atropine (1 mM) prior to
injection of a saline solution containing atropine (1 mM)
mixed with isoprenaline, MPB compounds or a cocktail
isoprenaline + CFTR potentiator. We determined the
secretory rate by dividing the weight of sample by the
number of minutes required for collection. The total saliva
secretion was determined by addition of all the samples
collected during the experiment after addition of isoprenaline
alone or isoprenaline+CFTR potentiator. These parameters
were then normalized by dividing the result by the weight in
grams of the mouse.
2.3. Chemicals
All compounds were from Sigma (St Louis, MO, USA)
except genistein obtained from LC laboratories (PKC
Pharmaceuticals, Inc, Woburn, MA, USA). MPB compounds
(MPB-05: 6-hydroxybenzo[c]quinolizinium chloride; MPB-
07: 10-chloro-6-hydroxybenzo[c]quinolizinium chloride)
were synthesized in our laboratory [11,12]. Compounds
were diluted at the appropriate concentration in a filtered
NaCl 0.9% solution excepted genistein which was dissolved
in ethanol.
2.4. Data analysis and statistics
All the data are presented as mean value±SEM, where n
refers to the number of experiments (i.e. animals). The
student's t-test was used. All graphs are plotted with
GraphPad prism 4.0 for Windows (GraphPad Software,
San Diego, CA, USA). Values of Pb0.05 were considered
statistically significant: ⁎Pb0.05, ⁎⁎Pb0.01, ⁎⁎Pb0.001.
Non significant (ns) difference was PN0.05.
3. Results
We first tested the effect of the β-adrenergic agonist
isoprenaline on the salivary secretion of Cftr+/+ and Cftr−/−
mice. After adding atropine to block the cholinergic-
dependent secretion, isoprenaline induced in Cftr+/+ mice an
increase of salivary secretion (Fig. 2A) with an average rate of
34.47±3.7 μg min−1 g−1 at a concentration of 10 μM (n=6)
and 60.36±3.6 μg min−1 g−1 at 100 μM (n=5, Fig. 2C). With
Cftr−/− mice, we did not observe secretion as shown Fig. 2B.
The corresponding average secretory rate after adding 10 μM
or 100 μM isoprenaline (0.77±3 μg min−1 g−1; 0.72±3.5 μg
min−1 g−1 n=5) remained unchanged (Fig. 2C). The
calculated total saliva secretion collected during the whole
experiment in the presence of isoprenaline in Cftr+/+ mice
(10 μM isoprenaline: 0.51±0.1 mg g−1, n=6; 100 μM
isoprenaline: 0.83±0.12 mg g−1, n=5) was significantly
different (Pb0.05) from Cftr−/− mice (10 μM isoprenaline:0.21±0.03 mg g−1, n=5; 100 μM isoprenaline: 0.2±0.03 mg
g−1, n=5; Fig. 2D). These values are comparable to those
recently reported [10].
Next, we injected the CFTR potentiator MPB-07 (Fig. 1)
with isoprenaline and collected the saliva of Cftr+/+ and
Cftr−/− mice. In the presence of 10 μM of isoprenaline,
addition of 500 μM MPB-07 increased by 347% the peak
rate for Cftr+/+ mice (average secretory rate: 153.6±8.1 μg
min−1 g−1, n=5, Pb0.0001, Fig. 2A and 2C). We did not
observe increase of the peak rate for Cftr−/− mice (average
secretory rate: 0.44±0.35 μg min−1 g−1, n=5, Fig. 2B and
C). The total saliva secretion in Cftr+/+ mice in the presence
of MPB-07 increased by 337% (1.72±0.2 mg g−1, n=5,
Pb0.001) but remained unchanged for Cftr−/− mice (0.23±
0.02 mg g−1, n=5, Fig. 2D).
To determine if MPB-07 compound could generate a
cross-stimulation of the cholinergic pathway (i.e. do CFTR
potentiators influence cholinergic-mediated salivary
132 S. Noël et al. / Journal of Cystic Fibrosis 7 (2008) 128–133secretion), we also tested MPB-07 without atropine. No
effect of MPB-07 was detected in this experimental
condition (0.84±2.8 μg min−1 g−1 after injection of MPB-
07 and 0.65±2.3 μg min−1 g−1 after injection of NaCl 0.9%
alone, n=3 for each conditions, ns, data not shown).
To compare effect of MPB-07 to another known CFTR
potentiator, we tested genistein [14] in the presence of 10 μM
isoprenaline on Cftr+/+ mice. Because genistein is not water-
soluble, we first evaluated its vehicle ethanol. We found that
injection of 10 μM isoprenaline with ethanol 0.1% increased
salivary secretion (Fig. 3A) with an average salivary rate of
42.35±10.2 μg min−1 g−1 (n=4, Fig. 3B). This peak is not
significantly different when compared to the peak induced by
isoprenaline alone (34.47±3.7 μgmin−1 g−1, Fig. 2A and C).
The mean total saliva secreted during this set of experiments
was 0.51±0.027 mg g−1 (n=4, Fig. 3C). Addition of 50 μM
genistein potentiated the secretory response induced by
isoproterenol alone (Fig. 3A) and increased the peak ofFig. 5. Effect of MPB-05 compound on salivary secretion of Cftr+/+ mice.
(A) average of salivary rate in the presence of isoprenaline alone, or
combined with 500 μM of MPB-05. The dotted line indicates the effect of
MPB-07 for comparison. (B) Mean value of total saliva secretion collected
during the whole experiment as described in A. For these experiments,
4≤n≤6.saliva secretion to 121.13±5.7 μg min−1 g−1 (Pb0.01, n=4,
Fig. 3B) leading to a total salivary secretion of 1.065±
0.062 mg g−1 (n=4, Fig. 3C). No effect of genistein was
observed on salivary secretion of Cftr−/− mice (data not
shown). These observations suggest that genistein, likeMPB-
07, is a potent stimulator of salivary secretion and that ethanol
did not affect the secretory response.
We next focussed on the stimulation by MPB-07 of
salivary secretion. The stimulation of isoprenaline-induced
salivary secretion in Cftr+/+ mice by this compound was
concentration-dependent as shown in Fig. 4. The peak rate of
salivary flow increased by 179% (79.2±3.1 μg min−1 g−1,
n=5), 245% (108.5±20.1 μg min−1 g−1, n=5, Pb0.01) and
347% (153.7±8.1 μg min−1 g−1, n=5, Pb0.001), respec-
tively in the presence of 100 μM, 250 μM and 500 μM,
compared to 10 μM of isoprenaline alone (Fig. 4A). Total
saliva secretion significantly increased by 158% (0.81±
0.1 mg g−1, n=4), 211% (1.08±0.2 mg g−1, n=5) and 337%
(1.72±0.2 mg g−1, n=5, Fig. 4B).
Now we have established that MPB-07 has no effect on
salivary secretion in Cftr−/− mice, and to be certain of the
pharmacological effect of benzo[c]quinolizinium compounds
as CFTR potentiators, we tested an inactive analogue of
MPB-07, the compound MPB-05 (6-hydroxybenzo[c]quino-
lizinium chloride). MPB-05 was tested at 500 μM in the
presence of 10 μM of isoprenaline on Cftr+/+ mice (Fig. 5).
We found no effect of this compound, both on the peak rate of
salivary flow (53.6±2.9 μg min−1 g−1, n=4, compared to
10 μM of isoprenaline alone 44.26±3.74 μg min−1 g−1,
n=4, ns) (Fig. 5A) and on the total saliva secretion (0.53±
0.02 mg g−1, n=4, compared to isoprenaline alone 0.51±
0.1 mg g−1, n=5, ns, Fig. 5B).
4. Discussion
By using a simple salivary secretion assay developed by
Best and Quinton [10] we observed for the first time a
secretory response with water-soluble and or ethanol-soluble
CFTR potentiators after in vivo administration in mice. It is
important to note that this assay is not appropriate to test
hydrophobic drugs (i.e. DMSO-soluble compounds). We
confirmed that Cftr−/− mice salivary glands failed to respond
to β-adrenergic stimulation and also showed a dose dependent
potentiation of the isoprenaline-induced salivary secretion
with MPB-07, whereas MPB-05, an inactive analogue, has no
effect. Interestingly the compound MPB-05 (6-hydroxybenzo
[c]quinolizinium chloride) only differs from MPB-07 (10-
chloro-6-hydroxybenzo[c]quinolizinium chloride) by the lack
of the chlorine atom at C-10. This structural observation was
already observed in vitro [11,12] but is now confirmed in vivo.
Thus the two following observations (i) that MPB-07 has no
effect in knock-out mice for CFTR and (ii) that a structural
modification of the compound, blocking its ability to activate
CFTR, fails to stimulate salivary secretion, demonstrate that
MPB-07 specifically activates CFTR in mouse salivary gland.
We believe that the effect of benzo[c]quinolizinium
133S. Noël et al. / Journal of Cystic Fibrosis 7 (2008) 128–133compounds is due to direct interaction with CFTR protein.
Indeed, when we injected MPB-07 without isoprenaline, we
did not observe stimulation of salivary secretion inCftr+/+ and
Cftr−/−mice (data not shown) suggesting that phosphorylation
(dependent of the β-adrenergic pathway) is required prior the
drug effect. In previous study, we already showed that benzo
[c]quinolizinium compounds including MPB-07 had no effect
on the cellular cAMP level measured in vitro [11]. Therefore
in order to measure in vivo the stimulation of CFTR with
benzo[c]quinolizinium compounds, the phosphorylation of
CFTR is probably required before the action of the drug.
Our study, together with others [10,18] highlighted the
physiological role of cAMP-dependent CFTR chloride chan-
nel in salivary secretion. The mouse mandibular duct cells
contain a forskolin-activated chloride conductance with
properties similar to those of CFTR [19]. The chloride
current in these cells is quiescent in resting cells but can be
activated by norepinephrine, via the β-adrenergic pathway
again arguing for a role of CFTR into the regulation of ductal
electrolyte transport by β-adrenergic agonists [19].
In conclusion, with the perspective of finding therapeu-
tically active drugs for CF patients, our study demonstrates
the usefulness of the salivary secretion assay to investigate in
vivo, the effect of new pharmacological water- and ethanol-
soluble compounds and should help characterization of new
agents selected from chemical libraries after high throughput
screening assay [12,13,16]. Another interesting perspective
of this study is the fact that finding new agents able to
stimulate the salivary flow may also be useful in oral health-
related quality of life for individuals suffering from dry
mouth and hyposalivation [20].
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